Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 117Bevacizumab 113Cisplatin 105Docetaxel 82Cyclophosphamide 80Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65fludarabine 57Fulvestrant 57Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × tenalisib × Clear all
NCT06189209 2025-12-02

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Rhizen Pharmaceuticals SA

Phase 2 Recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡